MedTrace Logo

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

NCT03767322 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 558

Last updated 2018-12-06

No results posted yet for this study

Summary

A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)

Conditions

  • Contrast-induced Nephropathy
  • Contrast-induced Acute Kidney Injury

Interventions

DRUG

Allopurinol

Eligible patients will receive allopurinol 300 mg before and after coronary intervention

DRUG

Febuxostat

Eligible patients will receive febuxostat 80 mg before and after coronary intervention

DRUG

Placebo

Eligible patients will receive before and after coronary intervention

Sponsors & Collaborators

  • Salvador López Gil

    collaborator UNKNOWN

  • Armando Vázquez Rangel

    collaborator UNKNOWN

  • Instituto Nacional de Cardiologia Ignacio Chavez

    lead OTHER

Principal Investigators

  • Magdalena Madero, MD · Instituto Nacional de Cardiologia Ignacio Chavez

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2019-10-31
Completion
2019-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03767322 on ClinicalTrials.gov